Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTG6VJM)

DTT Name	Rhodopsin P23H mutant messenger RNA (RHO P23H mRNA)
Synonyms	Opsin-2
Gene Name	RHO
DTT Type	Clinical trial target	[1]
BioChemical Class	mRNA target
UniProt ID	OPSD_HUMAN
TTD ID	T63198
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MNGTEGPNFYVPFSNATGVVRSPFEYPQYYLAEPWQFSMLAAYMFLLIVLGFPINFLTLY VTVQHKKLRTPLNYILLNLAVADLFMVLGGFTSTLYTSLHGYFVFGPTGCNLEGFFATLG GEIALWSLVVLAIERYVVVCKPMSNFRFGENHAIMGVAFTWVMALACAAPPLAGWSRYIP EGLQCSCGIDYYTLKPEVNNESFVIYMFVVHFTIPMIIIFFCYGQLVFTVKEAAAQQQES ATTQKAEKEVTRMVIIMVIAFLICWVPYASVAFYIFTHQGSNFGPIFMTIPAFFAKSAAI YNPVIYIMMNKQFRNCMLTTICCGKNPLGDDEASATVSKTETSQVAPA
Function	Photoreceptor required for image-forming vision at low light intensity (PubMed:8107847, PubMed:7846071). Required for photoreceptor cell viability after birth (PubMed:2215617, PubMed:12566452). Light-induced isomerization of the chromophore 11-cis-retinal to all-trans-retinal triggers a conformational change that activates signaling via G-proteins (PubMed:8107847, PubMed:28524165, PubMed:26200343, PubMed:28753425). Subsequent receptor phosphorylation mediates displacement of the bound G-protein alpha subunit by the arrestin SAG and terminates signaling (PubMed:28524165, PubMed:26200343). {ECO:0000269\|PubMed:12566452, ECO:0000269\|PubMed:2215617, ECO:0000269\|PubMed:26200343, ECO:0000269\|PubMed:28753425, ECO:0000269\|PubMed:7846071, ECO:0000269\|PubMed:8107847, ECO:0000305\|PubMed:28524165}.
KEGG Pathway	6010 (hsa )
Reactome Pathway	( ) (R-HSA-2453902 ) (R-HSA-2485179 ) (R-HSA-2514859 ) (R-HSA-418594 ) (R-HSA-419771 ) (R-HSA-5620916 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
QR1123	DMIRCF1	Retinitis pigmentosa	9B70	Phase 1/2	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04123626) A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene. U.S.National Institutes of Health.